UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-43048
NERVGEN PHARMA
CORP.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s name)
1200 Brickell Avenue, Suite 1950 #IP
Miami, Florida 33131
Telephone: (778) 731-1711
(Address and telephone number of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F¨
Form 40-F x
EXPLANATORY NOTE
Chief Medical Officer Appointment
On November 18, 2026, NervGen Pharma Corp. (the
“Registrant” or “Company”) announced the appointment of Dr. Sam Jackson as Chief Medical Officer, effective December
7, 2026 (the “Effective Date”). Dr. Jackson will report directly to the Chief Executive Officer. A copy of the press release
announcing Dr. Jackson’s appointment is filed hereto as Exhibit 99.1.
Dr. Jackson, age 60, brings more than 20
years of industry experience leading clinical development for novel neurologic, immunologic and ophthalmic programs. Dr. Jackson previously
served as the Chief Medical Officer of Aditum Bio, a biotechnology investment and venture capital firm, where he managed the neuroscience
portfolio from August 2025 to December 2026. Prior to that, Dr. Jackson held senior clinical roles at clinical stage and public biotechnology companies. He was Chief Medical Officer of Neuron23 Inc., from April 2022 to May 2025, and Chief Medical Officer (interim) / Senior Vice President Clinical Development
at Alector, Inc. (Nasdaq: ALEC), from April 2020 to April 2022. Dr. Jackson is a board-certified physician and received his MD from the
University of Pennsylvania, an MBA from The Wharton School at the University of Pennsylvania and a BA from Stanford University.
Pursuant to an offer letter (the “Offer
Letter”), signed November 16, 2026, between NervGen US Inc., a wholly owned subsidiary of the Company (“NervGen U.S.”),
and Dr. Jackson governing the terms of his employment, Dr. Jackson will be paid an annualized base salary of $525,000. Beginning with
fiscal year 2027, he will be eligible to receive an annual incentive bonus with a target of 40% of his base salary, based on the achievement
of Company and individual performance objectives established by the Compensation Committee of the Board (the “Committee”).
Pursuant to a separate sign-on bonus agreement (the “Bonus Agreement”), Dr. Jackson will also receive a one-time sign-on bonus
of $208,000 in lieu of any 2026 annual bonus. The sign-on bonus is payable in two installments: $100,000 following the Effective Date
and $108,000 on or after March 31, 2027, subject to Dr. Jackson's continued employment through such date, and subject to certain adjustments
set forth in the Bonus Agreement.
The Company will grant Dr. Jackson stock
options (the “Options”) to purchase up to 1,156,135 common shares of the Company, effective on the Effective Date, with
an exercise price per share equal to the closing price of the Company's common shares on the Nasdaq Capital Market on the Effective
Date. The Options will be exercisable for a period of ten years and are scheduled to vest over a four-year period, with 25.0%
vesting on the first anniversary of the Effective Date and the remaining 75.0% vesting in thirty-six substantially equal monthly
installments thereafter, subject to Dr. Jackson’s continued service through each applicable vesting date. On the Effective
Date, and subject to the terms of the Offer Letter, the Company will also grant Dr. Jackson 50,000 restricted share units, which vest
in full only if at least 150 participants have been randomized and enrolled in the RESTORE study on or before August 1, 2027 and Dr.
Jackson remains in service through such milestone.
In addition, the Offer Letter provides that Dr.
Jackson will be eligible to participate in the employee benefit plans made available to the Company’s senior executives. It also
provides that he will enter into the Company’s standard form of indemnity agreement and be covered under its directors’ and
officers’ liability insurance.
Pursuant to the Offer Letter, if Dr. Jackson’s
employment is terminated by NervGen U.S. without cause or by Dr. Jackson for good reason outside a change in control period, NervGen U.S.
is obligated to (1) continue to pay Dr. Jackson’s base salary for nine months, (2) pay any earned but unpaid annual bonus for the
prior fiscal year and (3) pay the employer portion of his health coverage premiums under the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended (“COBRA”), for up to nine months. If such a termination occurs within three months before or twelve
months after a change in control, Dr. Jackson will be entitled to (1) a lump sum payment equal to twelve months of base salary plus 100%
of his target bonus, (2) any earned but unpaid prior-year bonus, (3) COBRA premiums for up to twelve months and (4) the vesting of all
outstanding and unvested time-based equity awards. Severance benefits are conditioned on Dr. Jackson’s execution of a general release
of claims. All incentive-based compensation is subject to the Company's Compensation Recovery Policy.
The foregoing descriptions of the Offer Letter
and Bonus Agreement do not purport to be complete and are subject to and qualified in their entirety by reference to the full text of
the Offer Letter and Bonus Agreement. A copy of the Offer Letter and Bonus Agreement are filed as Exhibit 10.1 to this Report on Form
6-K.
INCORPORATION BY REFERENCE
This Report on Form 6-K, including Exhibits
10.1 and 99.1, is incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-296217)
and the Registrant’s Registration Statements on Form S-8 (File Nos. 333-292927 and 333-295632), to be a part thereof from the date
on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
DOCUMENTS INCLUDED AS PART OF THIS REPORT
| Exhibit |
|
|
| |
|
|
| 10.1 |
|
Offer Letter and Sign-On Bonus Agreement by and between NervGen U.S. and Sam Jackson, signed November 16, 2026. |
| 99.1 |
|
Press Release, dated November 18, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
NERVGEN PHARMA CORP. |
| |
|
|
| Date: November 18, 2026 |
By: |
/s/ Adam Rogers |
| |
|
Name: Adam Rogers |
| |
|
Title: Chief Executive Officer |
Exhibit 99.1
NervGen Appoints Neuroscience Drug Development
Leader Sam Jackson, MD, MBA, as Chief Medical Officer
| · | Dr. Jackson brings expertise in innovative neuroscience trial design, leading pivotal Phase 3 studies
and supporting FDA approval |
| · | He will lead execution of the ongoing Phase 3 RESTORE study and support clinical expansion of NVG-291
as a potential pipeline-in-a-product |
MIAMI – November 18, 2026 – NervGen
(NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord
injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Sam Jackson, MD, MBA, as Chief Medical
Officer. Dr. Jackson will work alongside the Chief Executive Officer and Board of Directors to shape and execute the Company’s clinical
development strategy.
Dr. Jackson has extensive experience in designing
and executing clinical trials in neuroscience, most recently in cervical dystonia, Parkinson’s disease, Alzheimer’s disease
and frontotemporal dementia. He has led clinical teams, designed cutting-edge clinical trials, built development organizations and contributed
to regulatory submissions resulting in FDA approval.
“Sam
is an accomplished physician-scientist and proven drug developer with expertise in innovative neuroscience trial design and experience
advancing therapies through pivotal development and approval,” said Adam Rogers, MD, President and Chief Executive Officer of NervGen.
“We are thrilled to welcome him to NervGen as we continue to strengthen our organization, advance through late-stage development
and seek to realize the potential of NVG-291 as a pipeline-in-a-product.
Sam will be instrumental in shaping our strategy for additional indications and strengthening our execution of RESTORE to deliver what
could be the first therapy to enable the nervous system to repair itself.”
Dr. Jackson most recently served as Chief Medical
Officer, Neuroscience at Aditum Bio, leading clinical development teams across its neuroscience portfolio. Previously, he was Chief Medical
Officer at Neuron23, where he designed and implemented the first global Phase 2 trial in Parkinson’s disease incorporating a companion
diagnostic and a digital primary endpoint. At Alector, he served as Senior Vice President of Clinical Development and interim Chief Medical
Officer and was clinical lead for the pivotal Phase 3 INFRONT-3 trial in frontotemporal dementia and the Phase 2 INVOKE-2 trial in Alzheimer’s
disease.
As Chief Medical Officer at Alkahest, Dr. Jackson
built the clinical organization and initiated multiple Phase 2 trials across neurological and ophthalmic indications. As Executive Director
of Clinical Development and Drug Safety at Dynavax Technologies, he was clinical lead and medical monitor for the 8,500-patient pivotal
Phase 3 trial of HEPLISAV-B, a hepatitis B vaccine, and contributed to the regulatory submission that led to FDA approval. Earlier in
his career, he held clinical development roles at Genentech and Amgen.
“NervGen’s
novel approach to overcoming the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs) with a subcutaneously administered therapy
is very exciting, and the findings from the Phase 1b/2a CONNECT SCI study reinforce my confidence in NVG-291’s
transformative potential for people living with spinal cord injury and other forms of nervous system damage,” said Sam Jackson,
MD, MBA, Chief Medical Officer of NervGen. “I look forward to advancing NVG-291 through RESTORE toward potential regulatory approval
and realizing its broader potential across additional indications associated with CSPG upregulation.”
Dr. Jackson is a board-certified emergency physician.
He earned his undergraduate degree from Stanford University and his MD and MBA from the University of Pennsylvania, where he was a Twenty-First
Century Scholar. He completed his emergency medicine residency at the University of California, Davis Medical Center and his medical toxicology
fellowship at Banner Good Samaritan Hospital in Phoenix.
About the Phase 3 RESTORE Study
RESTORE
is a multicenter, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating the efficacy and safety of NVG-291
in adults living with chronic traumatic cervical motor-incomplete SCI.
The study is expected to enroll approximately 150 participants across the United States and Canada. The study’s primary endpoint
assesses improvement in hand function, a leading recovery priority for individuals with cervical SCI, as measured by GRASSP Quantitative
Prehension. Secondary endpoints and blinded participant interviews will provide additional insight into functional independence and quality
of life. Eligible participants are one to ten years following a traumatic SCI, have a motor level at C7 or higher on both sides and have
an American Spinal Injury Association (ASIA) Impairment Scale classification of C or D. Participants will be randomized 1:1 to receive
NVG-291 or placebo by once-daily subcutaneous injection for 12 weeks,
followed by a four-week observation period. An optional 12-week open-label extension is planned following study completion. For additional
information, including eligibility criteria and study locations, visit ClinicalTrials.gov (identifier: NCT07799532).
About NervGen
NervGen
(NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord
injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals
living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291,
is a subcutaneously administered neuroreparative peptide designed to counteract the inhibitory effects of chondroitin sulfate proteoglycans.
NVG-291 has received Breakthrough Therapy designation from the FDA for
the treatment of chronic traumatic cervical motor-incomplete SCI, based
on preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study indicating the potential for substantial improvement over available
therapy on one or more clinically significant endpoints. NVG-291 has
also received FDA Fast Track designation and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. For
more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This
news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable
securities laws (collectively, “forward-looking statements”). Statements regarding the Company’s current and future
plans, expectations and intentions, results, levels of activity, performance, goals or achievements, and other future events or developments
constitute forward-looking statements. The words “may”, “will”, “would”, “should”, “could”,
“expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”,
“predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable
words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements
relating to: the potential benefits of Breakthrough Therapy designation; Dr. Jackson’s anticipated contributions to the Company’s
clinical development strategy, medical affairs activities and execution of RESTORE; the design, conduct, expected enrollment and anticipated
timelines of the RESTORE study, including the planned open-label extension; the Company’s plans to advance NVG-291
toward potential regulatory approval and expand its clinical development into additional indications; the potential therapeutic benefits
and broader applications of NVG-291, including its potential as a pipeline-in-a-product
and to enable the nervous system to repair itself; the development and potential therapeutic benefits of the Company’s product candidates;
and other factors described in the “Risk Factors” section of the Company’s most recently filed Annual Information Form
and Annual Report on Form 40-F/A, its amended and restated management’s discussion and analysis for the year ended December 31,
2025, and subsequent filings with Canadian securities regulators and the U.S. Securities and Exchange Commission. These documents are
available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the SEC’s website at www.sec.gov. Breakthrough
Therapy designation does not guarantee regulatory approval of NVG-291,
and results from earlier clinical studies may not be predictive of results from subsequent studies. Readers should not place undue reliance
on forward-looking statements made in this news release. Unless otherwise stated, the forward-looking statements contained in this news
release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Contacts
On365 Partners, Investor Relations
ir@nervgen.com
203.293.8091